BamSEC and AlphaSense Join Forces
Learn More

Eledon Pharmaceuticals Inc. – Material Contracts

NASDAQ: ELDN    
Share price (4/24/26): $3.46    
Market cap (4/24/26): $263 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.23
from 10-K 3 pages December 30, 2025 Steven Perrin Re: Voluntary Cancellation of Certain Option Grants
12/34/56
EX-10.22
from 10-K 3 pages December 30, 2025 David-Alexandre Gros Re: Voluntary Cancellation of Certain Option Grants
12/34/56
EX-10.26
from 10-K 3 pages Eledon Pharmaceuticals, Inc. By: Title: Accepted and Agreed: By: [Name]
12/34/56
EX-10.25
from 10-K 3 pages Eledon Pharmaceuticals, Inc. By: Title: Accepted and Agreed: By: [Name]
12/34/56
EX-10.14
from 10-K 3 pages Material contract
12/34/56
EX-10.8
from 10-K 52 pages Lease Blanchard Woods 78 Blanchard Road, Burlington, Massachusetts Premises: Approximately 6,138 Rentable Square Feet of Space on the Third (3rd) Floor of the Building Tenant: Eledon Pharmaceuticals, Inc
12/34/56
EX-10.7
from 10-K 13 pages Fourth Amendment to Lease
12/34/56
EX-10.1
from 8-K 17 pages Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan
12/34/56
EX-10.2
from 8-K 50 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 65 pages Securities Purchase Agreement
12/34/56
EX-10.23
from 10-K 3 pages Eledon Pharmaceuticals, Inc. December 30, 2023 [ ] Re: Amendment to Stock Option Agreement
12/34/56
EX-10.22
from 10-K 6 pages Eledon Pharmaceuticals, Inc. Stock Option Agreement Granted Under 2020 Long Term Incentive Plan 1) Grant of Option. A)
12/34/56
EX-10.1
from 8-K 18 pages Indemnification Agreement
12/34/56
EX-10.1
from 8-K 18 pages Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan
12/34/56
EX-10
from 8-K 3 pages Material contract
12/34/56
EX-10
from 8-K 5 pages Material contract
12/34/56
EX-10
from 8-K 66 pages Registration Rights Agreement
12/34/56
EX-10
from 8-K 85 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 10-Q 25 pages Licence Agreement Between Lonza Sales AG and Anelixis Therapeutics LLC
12/34/56
EX-10.2
from 10-Q 5 pages First Amendment to Restated License Agreement Between Als Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc
12/34/56